Literature DB >> 34802089

High-resolution ultrasound of peripheral nerves in late-onset hereditary transthyretin amyloidosis with polyneuropathy: similarities and differences with CIDP.

Luca Leonardi1, Giuseppe Di Pietro2, Antonella Di Pasquale3, Fiammetta Vanoli3, Laura Fionda3, Matteo Garibaldi3, Eleonora Galosi2, Girolamo Alfieri3, Antonio Lauletta3, Stefania Morino3, Marco Salvetti3,4, Andrea Truini2, Giovanni Antonini3.   

Abstract

INTRODUCTION: Hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) remains a diagnostic challenge due to clinical, neurophysiological, and laboratory findings suggestive of other diagnoses, particularly chronic inflammatory demyelinating polyneuropathy (CIDP). In this cross-sectional prospective study, we aimed to investigate the utility of high-resolution ultrasonography of peripheral nerves as a diagnostic tool to differentiate ATTRv-PN from CIDP.
METHODS: In 11 treatment-naive patients with genetically confirmed late-onset ATTRv-PN and 25 patients with CIDP, we collected clinical, electrodiagnostic, and high-resolution ultrasonography data of the peripheral nerves. In each patient, we used high-resolution ultrasonography to assess 26 nerve sites.
RESULTS: Of the 11 patients with ATTRv-PN, two had electrodiagnostic study data compatible with a CIDP diagnosis. High-resolution ultrasonography showed that the cross-sectional area of the brachial plexus, median nerve at the axilla, arm, and forearm, ulnar nerve at the forearm, and peroneal nerve at the popliteal fossa were significantly smaller in the 11 ATTRv-PN patients than in CIDP patients. However, in the two patients with electrodiagnostic study data compatible with a CIDP diagnosis, high-resolution nerve ultrasonography data were comparable to those in patients with CIDP.
CONCLUSION: Although high-resolution ultrasonography of peripheral nerves provides reliable information in patients with ATTRv-PN, its usefulness as a standalone diagnostic tool to differentiate ATTRv-PN from CIDP might be limited.
© 2021. Fondazione Società Italiana di Neurologia.

Entities:  

Keywords:  ATTRv-PN; CIDP; Hereditary transthyretin amyloidosis with polyneuropathy; High-resolution ultrasonography

Mesh:

Year:  2021        PMID: 34802089     DOI: 10.1007/s10072-021-05749-3

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.830


  21 in total

1.  Peripheral nerve ultrasound changes in CIDP and correlations with nerve conduction velocity.

Authors:  Antonella Di Pasquale; Stefania Morino; Simona Loreti; Elisabetta Bucci; Nicola Vanacore; Giovanni Antonini
Journal:  Neurology       Date:  2015-01-28       Impact factor: 9.910

2.  Diagnostic value of sonography in treatment-naive chronic inflammatory neuropathies.

Authors:  H Stephan Goedee; W Ludo van der Pol; Jan-Thies H van Asseldonk; Hessel Franssen; Nicolette C Notermans; Alexander J F E Vrancken; Michael A van Es; Stavros Nikolakopoulos; Leo H Visser; Leonard H van den Berg
Journal:  Neurology       Date:  2016-12-07       Impact factor: 9.910

Review 3.  Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

Authors:  David Adams; Haruki Koike; Michel Slama; Teresa Coelho
Journal:  Nat Rev Neurol       Date:  2019-06-17       Impact factor: 42.937

4.  Ultrasound evaluation in transthyretin-related amyloid neuropathy.

Authors:  Giuseppe Granata; Marco Luigetti; Daniele Coraci; Alessandra Del Grande; Angela Romano; Giulia Bisogni; Placido Bramanti; Paolo Maria Rossini; Mario Sabatelli; Luca Padua
Journal:  Muscle Nerve       Date:  2014-06-16       Impact factor: 3.217

5.  Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy.

Authors:  H Koike; K Misu; M Sugiura; M Iijima; K Mori; M Yamamoto; N Hattori; E Mukai; Y Ando; S Ikeda; G Sobue
Journal:  Neurology       Date:  2004-07-13       Impact factor: 9.910

6.  Correction to: Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin-mediated amyloidosis.

Authors:  Alejandra González-Duarte; John L Berk; Dianna Quan; Michelle L Mauermann; Hartmut H Schmidt; Michael Polydefkis; Márcia Waddington-Cruz; Mitsuharu Ueda; Isabel M Conceição; Arnt V Kristen; Teresa Coelho; Cécile A Cauquil; Céline Tard; Madeline Merkel; Emre Aldinc; Jihong Chen; Marianne T Sweetser; Jing Jing Wang; David Adams
Journal:  J Neurol       Date:  2020-03       Impact factor: 4.849

Review 7.  Guideline of transthyretin-related hereditary amyloidosis for clinicians.

Authors:  Yukio Ando; Teresa Coelho; John L Berk; Márcia Waddington Cruz; Bo-Göran Ericzon; Shu-ichi Ikeda; W David Lewis; Laura Obici; Violaine Planté-Bordeneuve; Claudio Rapezzi; Gerard Said; Fabrizio Salvi
Journal:  Orphanet J Rare Dis       Date:  2013-02-20       Impact factor: 4.123

8.  Estimating the global prevalence of transthyretin familial amyloid polyneuropathy.

Authors:  Hartmut H Schmidt; Márcia Waddington-Cruz; Marc F Botteman; John A Carter; Avijeet S Chopra; Markay Hopps; Michelle Stewart; Shari Fallet; Leslie Amass
Journal:  Muscle Nerve       Date:  2018-02-01       Impact factor: 3.217

Review 9.  Neuromuscular ultrasound in clinical practice: A review.

Authors:  Natalia L Gonzalez; Lisa D Hobson-Webb
Journal:  Clin Neurophysiol Pract       Date:  2019-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.